Optimi Health Completes First Psilocybin Export to UK for Planned Phase 2 Trial

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the completion of its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules manufactured at the company's GMP facility in Princeton, British Columbia.

The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression and were exported under authorization from Health Canada and the UK Home Office. The company noted that the products were cultivated, extracted and manufactured in-house under its Drug Establishment Licence, reinforcing its position as a vertically integrated GMP supplier supporting both regulated patient access programs and clinical research initiatives.

This development is significant as it demonstrates the growing international acceptance of psychedelic-based therapies and the ability of companies like Optimi to navigate complex regulatory frameworks. The export to the UK for a Phase 2 trial suggests progress in clinical research that could lead to new treatment options for mental health conditions.

Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, visit www.optimihealth.ca or optimi.net.

The full press release is available at https://ibn.fm/WLDHZ.